Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Preserving Antibiotics for the Future

Get Smart About Antibiotics Week: November 18–24, 2013

Did you know?

  1. Antibiotic resistance is one of the world’s most pressing public health threats.
  2. Antibiotics are the most important tool we have to combat life-threatening bacterial diseases, but antibiotics can have side effects.
  3. Antibiotic overuse increases the development of drug–resistant germs.
  4. Patients, clinicians, healthcare facility administrators, and policy makers must work together to employ effective strategies for improving antibiotic use — ultimately improving medical care and saving lives.

Looking ahead at the problem

  • No single strategy can solve the issue of antibiotic resistance; a multi‐pronged approach is required.
  • There are four core actions that will help fight these deadly infections:
    • Preventing infections and preventing the spread of resistance
    • Tracking resistant bacteria
    • Improving the use of today’s antibiotics
    • Promoting the development of new antibiotics and developing new diagnostic tests for resistant bacteria

Core Actions to Prevent Antibiotic Resistance

  1. Preventing Infections, Preventing The Spread of Resistance
  2. Tracking
  3. Improving Antibiotic Prescribing/Stewardship
  4. Developing New Drugs and Diagnostic Tests

Bacteria will inevitably find ways of resisting the antibiotics we develop, which is why aggressive action is needed now to keep new resistance from developing and to prevent the resistance that already exists from spreading. Combating resistance will take significant effort from clinicians, healthcare facility leaders, policy makers, and the agriculture industry.

To raise awareness and engage stakeholders, CDC recently released Antibiotic Resistance Threats in the United States, 2013, a snapshot of the complex problem of antibiotic resistance today and the potentially catastrophic consequences of inaction. In addition, more than 25 national organizations signed in 2012 a joint statement led by CDC and The Center for Disease Dynamics, Economics, and Policy supporting action to preserve antibiotic effectiveness and prevent resistance.

Top of Page

Why we must act now

  • The way we use antibiotics today or in one patient directly impacts how effective they will be tomorrow or in another patient; they are a shared resource.
  • Antibiotic resistance is not just a problem for the person with the infection. Some resistant bacteria have the potential to spread to others – promoting antibiotic‐resistant infections.
  • Since it will be many years before new antibiotics are available to treat some resistant infections, we need to improve the use of antibiotics that are currently available.

Top of Page

Changing the way we think about antibiotics for the future

  • Antibiotic use is a healthcare-quality issue that impacts patient safety.
  • Investments in appropriate antibiotic use will pay off, saving lives and money.
  • Healthcare facilities must have support for antibiotic stewardship interventions and programs in order to manage antibiotic use.
  • Ensuring the success of antibiotic stewardship programs is a collective effort.
  • Resistant organisms will continue to develop, so it is important that we continue to pursue the development of new antibiotics while preserving the ones we have today.

Top of Page

Vaccines as a tool for addressing antimicrobial resistance

  • Developing new vaccines can decrease rates of antibiotic-resistant infections. The first pneumococcal conjugate vaccine (PCV7) was licensed in the U.S. for use in infants and children in 2000. The newest pneumococcal conjugate vaccine (PCV13) replaced PCV7 in 2010.
  • PCV13 provides an opportunity to prevent even more antibiotic-resistant infections of pneumococcal disease since it protects against six additional strains of pneumococcus bacteria.
  • After introduction of PCV13 (2010-2011), cases of pneumococcal disease resistant to penicillin decreased by 48‰ compared to the pre-PCV13 period.

Top of Page

Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    TTY: (888) 232-6348
  • Contact CDC–INFO The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #